Delayed administration of sodium thiosulfate in animal models reduces platinum ototoxicity without reduction of antitumor activity

Clinical Cancer Research

Volumn 6, Issue 1, 2000, Pages 309-315

  Muldoon, Leslie L ^a,c   Pagel, Michael A ^d   Kroll, Robert A ^a   Brummett, Robert E ^c   Doolittle, Nancy D ^a   Zuhowski, Eleanor G ^e   Egorin, Merrill J ^e   Neuwelt, Edward A ^a,b,d,f  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^d PORTLAND VA MEDICAL CENTER   (United States)

^e UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^f NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; ETOPOFOS; ETOPOSIDE; PLATINUM; SODIUM THIOSULFATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER; CONTROLLED STUDY; CYTOTOXICITY; DRUG MECHANISM; GUINEA PIG; HEARING LOSS; MALE; NONHUMAN; OTOTOXICITY; PRIORITY JOURNAL; TREATMENT PLANNING;

ANIMALS; ANTIDOTES; AUDITORY THRESHOLD; CARBOPLATIN; CARCINOMA, SMALL CELL; CISPLATIN; DRUG ADMINISTRATION SCHEDULE; EAR, MIDDLE; ETOPOSIDE; FEMALE; GUINEA PIGS; HUMANS; LUNG NEOPLASMS; MALE; RATS; RATS, LONG-EVANS; RATS, NUDE; THIOSULFATES; TUMOR CELLS, CULTURED;

EID: 0033959645     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Williams, P. C., Henner, W. D., Roman-Goldstein, S., Dahlborg, S. A., Brummett, R. E., Tableman, M., Dana, B. W., and Neuwelt, E. A. Toxicity and efficacy of carboplatin and Etoposide in conjunction with blood-brain barrier modification in the treatment of intracranial neoplasms. Neurosurgery, 37: 1-12, 1995.
2. Lokich, J., and Anderson, N. Carboplatin versus cisplatin in solid tumors: an analysis of the literature. Ann. Oncol., 9: 13-21, 1998.
3. McKeage, M. J. Comparative adverse effect profiles of platinum drugs. Drug Safety, 13: 228-244, 1995.
4. Blakley, B. W., and Myers, S. F. Patterns of hearing loss resulting from cis-pladnum therapy. Otolaryngol. Head Neck Surg., 109: 385-391, 1993.
5. Kennedy, I. C. S., Fitzharris, B. M., Colls, B. M., and Atkinson, C. H. Carboplatin is ototoxic. Cancer Chemother. Pharmacol., 26: 232-234, 1990.
6. Macdonald, M. R., Harrison, R. V., Wake, M., Bliss, B., and Macdonald, R. E. Ototoxicity of carboplatin: comparing animal and clinical models at the hospital for sick children, J. Otolaryngol., 23: 151-159, 1994.
7. Parsons, S. K., Neault, M. W., Lehmann, L. E., Brennan, L. L., Eickhoff, C. E., Kretschmar, C. S., and Diller, L. R. Severe ototoxicity following carboplatin-containing conditionaing regimen for autologous marrow transplantation for neuroblastoma. Bone Marrow Transplant., 22: 669-674, 1998.
8. Neuwelt, E. A., Brummett, R. E., Remsen, L. G., Kroll, R. A., Pagel, M. A., McCorrnick, C. I., Guitjens, S., and Muldoon, L. L. In Vitro and animal studies of sodium thiosulfate as a potential chemoprotectant against carboplatin-induced ototoxicity. Cancer Res., 56: 706-709, 1996.
9. Gandara, D. R., Perez, E. A., Wiebe, V., and De Gregorio, M. W. Cisplatin chemoprotection and rescue: pharmacologic modulation of toxicity. Semin. Oncol., 18(Suppl. 3): 49-55, 1991.
10. Dedon, P. C., and Borch, R. F. Characterization of the reactions of platinum antitumor agents with biologic and nonbiologic sulfur-containing nucleophiles. Biochem. Pharmacol., 36: 1955-1964, 1988.
11. Elferink, F., Van der Vugh, W. J. F., Klein, I., and Pinedo, H. M. Interaction of cisplatin and carboplatin with sodium thiosulfate: reaction rates and protein binding. Clin. Chem., 32: 641-645, 1988.
12. Iwamato, Y., Kawano, T., Uozumi, J., Aoki, K., and Baba, T. "Two-route chemotherapy" using high-dose ip cisplatin and iv sodium thiosulfate, its antidote, for peritoneally disseminated cancer in mice. Cancer Treat. Rep., 68: 1367-1373, 1984.
13. Howell, S. B., Pfeifle, C. L., Wung, W. E., Olshen, R. A., Lucas, W. E., Yon, J. L., and Green, M. Intraperitoneal cisplatin with systemic thiosulfate protection. Ann. Intern. Med., 97: 845-851, 1982.
14. Pfeifle, C. E., Howell, S. B., Felthouse, R. D., Woliver, T. B. S., Andrews, P. A., Markman, M., and Murphy, M. P. High-dose cisplatin with sodium thiosulfate protection. J. Clin. Oncol., 3: 237-244, 1985.
15. Neuwelt, E. A., Brummett, R. E., Doolittle, N. D., Muldoon, L. L., Kroll, R. A., Pagel, M. A., Dojan, R., Church, V., Remsen, L., and Bubalo, J. S. First evidence of otoprotection against carboplatin-induced hearing loss with a two compartment system in patients with CNS malignancy. J. Pharmacol. Exp. Ther., 286: 77-84, 1998.
16. 2 and other factors on osmotic blood-brain barrier disruption in rats with brain tumor xenografts. Anesth. Analg., 88: 559-567, 1999.
17. Ivankovich, A. D., Braverman, B., Stephens, T. S., Shulman, M., and Heyman, H. J. Sodium thiosulfate dispostion in humans: relation to sodium nitroprusside toxicity. Anesthesiology, 58: 11-17, 1983.
18. Erkmen, K., Egorin, M. J., Reyno, L. M., Morgan, R. Jr, and Doroshow, J. H. Effects of storage on the binding of carboplatin to plasma proteins. Cancer Chemother. Pharmacol., 35: 254-256, 1995.
19. Saito, T., Zhang, Z. J., Manabe, Y., Ohtsubo, T., and Saito, H. The effect of sodium thiosulfate on ototoxicity and pharmacokinetics after cisplatin treatment in guinea pigs. Eur. Arch. Oto-Rhino-Laryngol., 254: 281-286, 1997.
20. Jones, M. M., and Basinger, M. A. Thiol and thioether suppression of cis-platinum-induced nephrotoxicity in rats bearing the walker 256 carcinosarcoma. Anticancer Res., 9: 1937-1942, 1989.
21. Inoue, M., Shimizu, C., Shimizu, H., and Tanizawa, O. Neutralizing effect of sodium thiosulfate on antitumor efficacy of cisplatin for human carcinoma xenografts in nude mice. Gynecol. Oncol., 40: 34-37, 1991.
22. Schlichter LM. Exploration of platinum-based dose-intensive chemotherapy strategies with amifostine (Ethyol). Eur. J Cancer, 32A (Suppl 4): S40-S42, 1996.
23. Schiller, J. H. High-dose cisplatin and vinblastine plus amifostine for metastatic non-small cell lung cancer. Semin. Oncol., 23(4 Suppl. 8): 78-82, 1996.
24. Ramnath, N., LoRusso, P., Simon, M., and Martino, S. Phase II evaluation of cisplatin and WR2721 for refractory metastatic breast cancer. Am. J. Clin. Oncol., 20: 368-372, 1997.
25. Berry, J. M., Jacobs, C., Sikic, B., Halsey, J., and Borch, R. F. Modification of cisplatin toxicity with diethyldithiocarbamate. J. Clin. Oncol., 8: 1585-1590, 1990.
26. Campbell, K. C. M., Rybak, L. P., Meech, R. P., and Hughes, L. D-methionine provides excellent protection from cisplatin ototoxicity in the rat. Hearing Res., 102: 90-98, 1996.
27. Gabaizadeh, R., Staecker, H., Liu, W., Kopke, R., Malgrange, B., Lefebvre, P. P., and Van De Water, T. R. Protection of both auditory hair cells and auditory neurons from cisplatin induced damage. Acta Otolaryngol. (Stockh.), 117: 232-238, 1997.
28. Reed, E. Platinum-DNA adduct, nucleotide excision Repair and platinum based anti-cancer chemotherapy. Cancer Treat. Rev., 24: 331-344, 1998.